|
|
|
| Expression and significance of serum IL-37, TGF-β in patients with acute ST-segment elevation myocardial infarction |
| ZHOU Yaguang WU Huihui WANG Ronghua YANG Kun LIU Ya′nan WANG Kun HE Jingli PENG Chunxia |
| Department of Emergency, Civil Aviation General Hospital, Beijing 100123, China |
|
|
|
Abstract Objective To investigate the expression and significance of serum interleukin (IL)-37, transforming growth factor β (TGF-β) in patients with acute ST-segment elevation myocardial infarction (STEMI). Methods Forty patients with STEMI diagnosed and taken percutaneous coronary intervention (PCI) in Department of Emergency, Civil Aviation General Hospital from September 2014 to September 2015 were selected as experimental group, and 40 normal regular healthy control were selected as control group. The concentration of serum IL-37, TGF-β in peripheral blood was detected by enzyme-linked immunosorbent assay (ELISA). Results The concentration of serum IL-37 in experimental group was significantly higher than that of control group (P = 0.02), the concentration of TGF-β was significantly lower than that of control group, the difference was statistically significant (P = 0.000). The concentration of IL-37 was negatively correlated with TGF-β in experimental group (r = -0.79, P = 0.00), while there was no obvious correlation between IL-37 and TGF-β in control group (r = 0.03, P = 0.86). Conclusion Both IL-37 and TGF-β are involved in the inflammatory process of STEMI. IL-37 and TGF-β has a negative correlation in the inflammatory process of STEMI. The anti-inflammatory effect of IL-37 may be related to TGF-β.
|
|
|
|
|
|
[1] Hansson GK，Hermansson A. The immune system in ath?鄄erosclerosis [J]. Nat Immunol，2011，12（3）：204-212.
[2] Kumar S，McDonnell PC，Lehr R，et al. Identification and initial characterization of four novel members of the interleukin-1 family [J]. J Biol Chem，2000，275（14）：10308-10314.
[3] Dunn E，Sims JE，Nicklin MJ，et al. Annotating genes with potential roles in the immune system：six new mumbers of the IL-1 family [J]. Trends Immunol，2001，22（10）：533-536.
[4] Nold MF，Nold-Petry CA，Zepp JA，et al. IL-37 is a fundamental inhibitor of innate immunity [J]. Nat Immunol，2010， 11（11）：1014-1022.
[5] Boraschi D，Lucchesi D，Hainzl S，et al. IL-37：a new anti-inflammatory cytokine of the IL-1 family [J]. Eur Cytokine Netw，2011，22（3）：127-147.
[6] Tashiro H，Shimokawa H，Sadamatu K，et al. Prognostic significance of plasma concentrations of transforming growth factor-[beta] in patients with coronary artery disease [J]. Coron Artery Dis，2002，13（3）：139-143.
[7] 黄波，胡珺，郑宏超.冠心病患者血清TGF-β与IGF-1的相关性[J].中国老年病杂志，2014，34（3）：1368-1369.
[8] 黄瑛，林英忠，施莹，等.急性冠脉综合症患者血浆IL-37变化水平及意义[J].实用医学杂志，2014，30（10）：1559- 1561.
[9] Ji Q，Zeng Qi，Huang Y，et al. Elevated Plasma IL-37，IL-18，and IL-18BP Concentrations in Patients with Acute Coronary Syndrome [J]. Mediators Inflamm，2014，2014：165742.
[10] Libby P. Mechanisms of acute coronary syndromes and their implications for therapy [J]. N Engl J Med，2013， 368（21）：2004-2013.
[11] Dinarello CA. Overview of the interleukin-1 family of ligands and receptors [J]. Semin Immunol，2013，25（6）：389-393.
[12] Bulau AM，Fink M，Maucksch C，et al. In vivo expression of IL-37 reduces local and systemic inflammation in concanvalin A-induced hepatitis [J]. Sci World J，2011，11：2480-2490.
[13] Gunaltay S，Nyhlin N，Kumawat AK，et al. Differential expression of interleukin-1/Toll-like receptor signaling regulators in microscopic and ulcerative colitis [J]. World J Gastroenterol，2014，20：12249-12259.
[14] Yang Y，Zhang ZX，Lian D，et al. IL-37 inhibits IL-18-induced tubular epithelial cell expression of pro-inflammatory cytokines and renal ischemia reperfusion injury [J]. Kidney Int，2015，87（2）：396-408.
[15] Zhao JJ，Pan QZ，Pan K，et al. Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma：role for CD57+NK cells [J]. Sci Rep，2014，4：5177.
[16] Yang L，Zhang J，Tao J，et al. Elevated serum levels of Interleukin-37 are associated with inflammatory cytokines and disease activity in rheumatoid arthritis [J]. APMIS，2015， 123（12）：1025-1031.
[17] Weidlich S，Bulau AM，Schwerd T，et al. Intestinal expression of the anti-inflammatory interleukin-1 homologue IL-37 in pediatric inflammatory bowel disease [J]. J Pediatr Gastroenterol Nutr，2014，59（2）：e18-e26.
[18] Liu W，Deng L，Chen Y，et al. Anti-inflammatory effect of IL-37b in children with allergic rhinitis [J]. Mediators Inflamm，2014，2014：746846.
[19] Jinnin M，Ihn H，Tamaki K. Characterization of SIS3，a novel specific inhibitor of Smad3，and its effect on transforming growth fator-betal-induced extracellular matrix expression [J]. Mol Pharmacol，2006，69（2）：597-607.
[20] Marcin D，Wei Chen，Nikolaos GF. Transforming Growth Factor（TGF）-β signaling in cardiac remodeling [J]. J Mol Cell Cardiol，2011，51（4）：600-606.
[21] Euler G. Good and bad sides of TGFβ-signaling in myocardial infarction [J]. Front Physiol，2015，6：66.
[22] Derynck R，Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signaling [J]. Nature，2003，425（6958）：577-584.
[23] Duan Y，Zhu W，Liu M，et al. The expression of Smad signaling pathway in myocardium and potential therapeutic effects [J]. Histol Histopathol，2016，11（15）：11845.
[24] Matsuzaki K. Smad phospho-isoforms direct context-dependent TGF-β signaling [J]. Cytokine Growth Factor Rev，2013，24（4）：385-399. |
|
|
|
